Pharvaris Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Pharvaris hat ein Gesamteigenkapital von €359.2M und eine Gesamtverschuldung von €0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen €377.6M bzw. €18.4M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

€0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	€343.57m
Eigenkapital	€332.77m
Gesamtverbindlichkeiten	€19.08m
Gesamtvermögen	€351.85m

Jüngste Berichte zur Finanzlage

Recent updates

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Aug 16

Pharvaris: Digging Deep For Sufficient Market Size

Jan 17

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Oct 09

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

May 13

Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth

Jan 11

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Sep 26

Pharvaris GAAP EPS of -€0.38

Sep 12

Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate

Aug 22

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Jun 08

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Dec 21

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Aug 25

Pharvaris reports Q1 results

May 26

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: PHVSDie kurzfristigen Aktiva des Unternehmens (€376.8M) übersteigen seine kurzfristigen Passiva (€18.4M).

Langfristige Verbindlichkeiten: PHVSDie kurzfristigen Vermögenswerte des Unternehmens (€376.8M) übersteigen seine langfristigen Verbindlichkeiten (€70.0K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: PHVS ist schuldenfrei.

Schulden abbauen: PHVS hat in den letzten 5 Jahren keine Schulden gemacht.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: PHVS auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.

Vorhersage Cash Runway: PHVS verfügt über eine ausreichende Liquiditätsreserve für 2.2 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 39.1% pro Jahr abnimmt.

Pharvaris Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Recent updates

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Pharvaris N.V. Announces Resignation of Morgan Conn as Chief Business Officer, Effective October 4, 2024

Co-Founder notifies of intention to sell stock

Pharvaris Expands Development Program for Deucrictibant

Co-Founder notifies of intention to sell stock

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris N.V. Appoints David Nassif as Permanent Chief Legal Officer

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Pharvaris N.V. Announces Chief Legal Officer Changes, Effective June 1, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Share price stability

Chief Early Development Officer notifies of intention to sell stock

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Independent Vice Chairman notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Pharvaris: Digging Deep For Sufficient Market Size

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-Demand Treatment of HAE At the GA²LEN UCARE Conference 2023

New major risk - Shareholder dilution

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris Announces Positive Top-Line Phase 2 Data from the Chapter-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Co-Founder notifies of intention to sell stock

Pharvaris Appoints Stefan Abele as Chief Technical Operations Officer

New major risk - Revenue and earnings growth

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Chief Medical Officer notifies of intention to sell stock

New major risk - Share price stability

Co-Founder notifies of intention to sell stock

Pharvaris N.V. Announces Board Changes

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

Pharvaris Announces Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

Pharvaris N.V., Annual General Meeting, Jun 23, 2023

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

Less than half of directors are independent

Pharvaris Presents Data Supporting HAE Drug Development Strategy At the 2022 HAEi Global Leadership Workshop

Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris GAAP EPS of -€0.38

Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S

Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V., Annual General Meeting, Jun 29, 2022

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris N.V. Appoints Joan Schmidt as Chief Legal Officer

Less than half of directors are independent

High number of new and inexperienced directors

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris reports Q1 results

Independent Non-Executive Director has left the company

Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE

Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE

Pharvaris B.V. has completed an IPO in the amount of $165.41 million.

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen